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 Cancer cells develop a lipogenic phenotype that sup-
ports the energy and membrane synthesis requirements 
associated with the enhanced proliferation and survival 
under stress inherent to malignant progression ( 1, 2 ). The 
recognition of the importance of this phenotype in cancer 
has led to the use of enzymes of lipid metabolism as mark-
ers to monitor neoplastic progression and response to 
therapy, as well as to the development of drugs targeted at 
key lipogenic enzymes, such as fatty acid synthase (FASN) 
( 2, 3 ). The excess fatty acid synthesis that results from the 
coordinated activation of lipogenic enzymes in many 
types of cancer leads to the accumulation of palmitate, 
which needs to be further processed by the cells due to 
the toxic effects of its accumulation. One pathway that 
 Abstract  Acid ceramidase (AC) catalyzes the hydrolysis of 
ceramide into sphingosine, in turn a substrate of sphingosine 
kinases that catalyze its conversion into the mitogenic sphin-
gosine-1-phosphate. AC is expressed at high levels in several 
tumor types and has been proposed as a cancer therapeutic 
target. Using a model derived from PC-3 prostate cancer 
cells, the highly tumorigenic, metastatic, and chemoresistant 
clone PC-3/Mc expressed higher levels of the AC ASAH1 
than the nonmetastatic clone PC-3/S. Stable knockdown 
of ASAH1 in PC-3/Mc cells caused an accumulation of cer-
amides, inhibition of clonogenic potential, increased require-
ment for growth factors, and inhibition of tumorigenesis and 
lung metastases. We developed de novo ASAH1 inhibitors, 
which also caused a dose-dependent accumulation of cer-
amides in PC-3/Mc cells and inhibited their growth and clo-
nogenicity. Finally, immunohistochemical analysis of primary 
prostate cancer samples showed that higher levels of ASAH1 
were associated with more advanced stages of this neopla-
sia.  These observations confi rm ASAH1 as a therapeutic 
target in advanced and chemoresistant forms of prostate can-
cer and suggest that our new potent and specifi c AC inhibi-
tors could act by counteracting critical growth properties of 
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chemotherapeutic regimes ( 19, 20 ). Two major challenges 
in PC are to fi nd predictive markers that identify those 
tumors most likely to follow a hormone-independent, ag-
gressive clinical course as aids to decide early intervention 
and to identify molecular targets for improved therapies 
of castration-resistant cases that respond poorly to conven-
tional chemotherapeutic regimes. Here, we provide new 
evidence to reinforce the notion that the acid cerami-
dase ASAH1 is a valid therapeutic target in advanced 
prostate cancer, and we characterize new potent and 
specifi c inhibitors of AC. 
 METHODS 
 Cells and reagents 
 PC-3/Mc and PC-3/S cells ( 21 ) were grown in RPMI1640 me-
dium supplemented with 10% fetal bovine serum, nonessential 
amino acids, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml 
penicillin, and 100 µg/ml streptomycin (all from PAA, Ontario, 
Canada). Fibroblasts from a Farber patient (FD, wild-type) and 
FD transformed to stably overexpress AC (FD10X) were grown in 
a humidifi ed 5% CO 2 atmosphere at 37°C in DMEM medium 
supplemented as above. 
 Transient transfection of fi broblasts 
 Twenty-four hours before transfection, cells were plated at a 
density of 2.5 × 10 5 cells in 35 mm diameter plates. Cells were 
then transfected with the specifi c constructs or empty vectors us-
ing lipofectamine 2000 (Invitrogen, Carlsbad, CA). Twenty-four 
hours after transfection, cells were either processed immediately 
or collected by trypsinization, washed twice with PBS, and centri-
fuged. Pellets were stored at   20°C until use. In transfections with 
neutral ceramidase (NC), the success of transfection was con-
fi rmed by activity assays with CerC12NBD in intact cells. 
 Fluorogenic ceramidase assay 
 Cells were collected by trypsinization, washed with PBS, resus-
pended in 0.25 M sucrose and lysed by ultrasonication in an ul-
trasonic bath. For the assay, 75 µl of reaction buffer (100 mM 
sodium acetate buffer, pH 4.5, for acid ceramidase activity), con-
taining 40 µM RBM14C12 fl uorogenic substrate ( 22 ) (with or with-
out test compounds), was mixed with 25 µl of the cell lysates (20 µg 
of total protein content) and incubated at 37°C for 3 h. For time 
dependence of inhibition, incubations were carried out for 0.5, 
1, 2, and 3 h with different amounts of protein. The reaction was 
stopped by addition of methanol followed by NaIO 4 (2.5 mg/ml 
in 200 mM glycine/NaOH buffer, pH 10.6). After 1 h at 37°C, 
100   l of 200 mM glycine/NaOH buffer were added and fl uores-
cence detected at 355/460 nm excitation/emission wavelengths 
on a SpectraMax Microplate Reader (Molecular Devices, Sunny-
vale, CA). To determine ceramidase activity in intact cells, 2 × 10 4 
cells/well were seeded in 96-well plates (Nunc, Roskilde, Den-
mark). The following day, medium was replaced by 100   l fresh 
medium containing 40 µM RBM14C12 fl uorogenic substrate in-
cubated for 3 h at 37°C in a 5% CO 2 atmosphere, and the assay 
was continued as above. 
 Papain activity 
 Papain activity was determined in 96-well plates by a modifi ca-
tion of the reported procedure ( 23 ). The reaction mixture con-
tained 250 µl of 0.1 M phosphate buffer (pH 6.5) with 0.3 M KCl, 
0.1 mM EDTA, and 3 mM DTT; 30 µl of substrate solution 
(L-pyroglutamyl-L-phenylalanyl-L-leucine- p -nitroanilide; 2.2 mM 
many neoplastic cells activate to offset the toxic accumula-
tion of palmitate is its peroxisome proliferator-activated 
receptor (PPAR)  -dependent funneling to eventually form 
triglycerides, which can be further used as energy stores 
( 4 ). A second pathway followed by palmitate is the con-
densation of palmitoyl CoA with L-serine, leading to the 
synthesis of ceramides ( 5 ). The accumulation of ceramides 
also poses a problem for cell survival because of its proapop-
totic consequences ( 6–8 ). This can be counteracted by ac-
tivities that convert ceramides to a variety of metabolites, 
including sphingosines through deacylation catalyzed 
by ceramidases. Sphingosines can be converted into the 
growth- and survival-promoting sphingosine-1-phosphate 
(S1P) through the action of sphingosine kinases ( 8 ). S1P 
can be either irreversibly degraded by S1P lyase or reuti-
lized by sequential dephosphorylation and acylation for 
ceramide synthesis. The importance of ceramidases in the 
context of cancer is supported by the observation that 
their inhibition by drugs or RNAi severely compromises 
the growth and survival under stress of tumor cells ( 9 ). 
 De novo ceramide biosynthesis requires the coordi-
nate action of serine palmitoyl transferase and ceramide 
synthase to generate ceramide. This process begins with 
the condensation of serine and palmitoyl-CoA to form 
3-ketosphinganine ( 5 ), which is reduced to the sphingoid 
base sphinganine and acylated by ceramide synthase to 
generate dihydroceramide. This compound is oxidized to 
ceramide by introduction of a  trans -4,5 double bond. This 
pathway can be stimulated by drugs and ionizing radia-
tion and usually results in a prolonged ceramide accu-
mulation ( 10 ). 
 Once generated, ceramide may amass or be converted 
into a variety of metabolites. Phosphorylation by ceramide 
kinase ( 11 ) generates ceramide 1-phosphate, while deacy-
lation by alkali ne, neutral or acid ceramidases (the prod-
ucts of different genes) ( 12 ) yields sphingosine, which 
may be phosphorylated by sphingosine kinase to S1P. Two 
distinct sphingosine kinases have been cloned. These two 
isoforms differ in temporal patterns of expression during 
development, are expressed in different tissues, and pos-
sess distinct kinetic properties ( 13 ), implying that they 
perform different cellular functions. Ceramide may also 
be converted back to SM by transfer of phosphorylcholine 
from phosphatidylcholine via SM synthases ( 14 ). Alterna-
tively, it can be glycosylated by glucosylceramide synthase 
to form glucosylceramide, which may be further modifi ed 
by various enzymes in the Golgi apparatus to form com-
plex glycosphingolipids ( 15 ). 
 Many tumor types express high levels of acid cerami-
dase (AC). Specifi cally, the expression levels of AC in 
prostate cancer have been reported to be elevated relative 
to normal prostate tissue ( 16, 17 ). Prostate cancer (PC) is 
the most prevalent neoplasia in men in industrialized na-
tions ( 18 ). Although PC is frequently initially sensitive to 
hormonal deprivation therapies and follows indolent clin-
ical courses, a signifi cant proportion of cases eventually 
become resistant to such therapeutic approaches, accom-
panied with aggressive growth, establishment of metasta-
sis, and tumors that are highly resistant to conventional 
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480 Software release 1.5.0. The amplifi cation levels of RN18S1 
and HMBS were used as internal references to estimate the rela-
tive levels of specifi c transcripts, and relative quantifi cation was 
determined by the    Cp method. All determinations were done 
in triplicate. 
 Cell cycle analysis 
 Cells were seeded in 6-well Corning plates (Corning, NY), 
detached with Trypsin/EDTA/1% BSA, washed twice, resus-
pended in PBS, and fi xed at 4°C for at least 2 h by dropwise 
addition of 70% ethanol. Subsequently, cells were washed with 
PBS/50 mM EDTA/1% BSA and incubated with 1 mg/ml RNase A 
(Sigma) at 37°C for 1 h and 0.1 mg/ml propidium iodide 
(Sigma, Alcobendas, Madrid, Spain). DNA content was deter-
mined in a Cytomics FC500 instrument (Coulter, Hialeah, FL), 
and cell cycle distribution analyzed with Multicycle. All determi-
nations were done in triplicate. 
 Anchorage-independent growth 
 For soft-agar colony formation assays, 0.5% agar in complete 
culture medium was placed at the bottom of 12-well plates, al-
lowed to solidify, and overlayed with a suspension of 3 × 10 3 cells 
in 0.3% agar in complete medium. After solidifi cation, wells were 
fed with complete medium twice a week. After three weeks, they 
were fi xed with 0.5% glutaraldehyde, stained with 0.025% crystal 
violet, and visualized under a Leica magnifying glass (Wetzler, 
Germany) coupled to an Olympus digital camera (Olympus, 
Hamburg, Germany). Colonies   0.2 mm diameter were scored 
with the ImageJ software (National Institutes of Health, MD). 
Each experimental condition was performed in triplicate. 
 In vivo tumor formation 
 For localized growth, 1 × 10 3 to 1 × 10 5 cells with stably inte-
grated fi refl y luciferase were injected in a volume of 50 µl of 
RPMI 1640 (without FBS) intramuscularly in each hind limb of 
anesthetized six-week-old male NOD-SCID mice. Tumor growth 
was monitored by luminometry on an ORCA-2BT instrument 
(Hamamatsu Photonics, Hamamatsu, Japan), 5 min after intra-
peritoneal injection of luciferine (100 mg/kg in 150 µl of PBS). 
For lung colony formation, 5 × 10 5 cells in 150 µl RPMI1640 were 
injected through the dorsal caudal vein. Mice were imaged im-
mediately after injection, and thereafter, tumor development 
was monitored by weekly imaging. For bioluminescence plots, 
photon fl ux was calculated relative to background values from 
luciferin-injected mice with no tumor cells and normalized to the 
value obtained immediately after xenografting. In lung coloniza-
tion free survival analysis, lesions that had an increased photon 
fl ux value above day 0 were counted as events. 
 Production and transduction of lentiviral particles 
 Constructs based on the pLK0puro vector and bearing ASAH1-
targeting shRNAs or control sequences were purchased from 
Sigma-Aldrich. The lentivirus packaging cell line HEK293T was 
cotransfected with these DNAs, together with pCMVdeltaR8.91 
and pVSV-G (Clontech, Mountain View, CA) for 12 h using 
Fugene HD (Roche). Supernatants were collected for the fol-
lowing 48 h and fi ltered through 0.45 µm methylcellulose fi lters 
(Millipore, Billerica, MA). Lentiviral particles were concentrated 
by ultracentrifugation at 27,000 rpm for 90 min on 20% sucrose 
density gradients. Viral particles were resupended with medium 
and added to the cells together with 8 µg/ml polybrene (Sigma). 
Cells were infected for 24 h and allowed to recover in fresh me-
dium for 24–48 h. Selection for cells with integrated sequences 
was carried out for three days in medium supplemented with 
5 µg/ml puromycin (Biomol, Exeter, UK). 
in DMSO, 0.22 mM fi nal concentration); 20 µl of enzyme solu-
tion (30 µg/ml in reaction buffer); and 3 µl of inhibitor solu-
tion or vehicle. Chymostatin at 1 µM and 10 µM was used as 
positive control of inhibition of papain activity. The reaction 
was stopped by the addition of 20 µl of 1 N HCl, and the OD was 
measured at 410 nm. 
 Sphingolipid analysis by UPLC/MS 
 The liquid chromatography-mass spectrometry equipment 
consisted of a Waters Aquity UPLC system connected to a Wa-
ters LCT Premier orthogonal accelerated time of fl ight mass 
spectrometer (Waters, Millford, MA), operated in positive elec-
trospray ionization mode. Full scan spectra from 50 to 1,500 Da 
were acquired, and individual spectra were summed to produce 
data points every 0.2 s. Mass accuracy and reproducibility were 
maintained by using an independent reference spray by the 
LockSpray interference. The analytical column was a 100 mm × 
2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters). The two 
mobile phases were phase A: MeOH/H2O/HCOOH (74:25:1 
v/v/v); phase B: MeOH/HCOOH (99/1 v/v), both also con-
taining 5 mM ammonium formate. A linear gradient was pro-
grammed as follows: 0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 
15 min: 99% B; 18 min: 99% B; 20 min: 80% B, at 0.3 ml/min 
fl ow rate. The column was held at 30°C. Quantifi cation was car-
ried out using the extracted ion chromatogram of each com-
pound, using 50 mDa windows. Linear dynamic range was 
determined by injecting standard mixtures, and positive identifi -
cation of compounds was based on accurate mass measurement 
(< 5 ppm error) and LC retention time compared with that of a 
standard (± 2%). 
 HPLC/fl uorescence detection 
 These analyses were carried out in an Alliance Waters 2695 
HPLC system coupled to a Waters 2475 Multi   fl uorescence de-
tector (Waters, Milford USA) equipped with an Atlantis T3 C18 
(50 mm × 4.6 mm) column (Waters). The mobile phase was com-
posed of a mixture of acetonitrile/H2O (80:20), and the fl ow rate 
was set at 1 ml/min. All solvents contained 0.1% trifl uoroacetic 
acid. Fluorescent compounds were monitored at 420/483 nm 
excitation/emission wavelengths. Peak quantifi cation was car-
ried out using the Empower Pro 2.0 software (Waters). 
 Western blotting 
 Cells were lysed (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM 
Na 3 VO 4 , 1% Triton-X 100, 10% glycerol, 0.1% SDS, 0.5% deoxy-
cholate, 1 mM PMSF, 1 mg/ml aprotinine, and leupeptine), pro-
teins separated by SDS-polyacrylamide electrophoresis (Bio-Rad 
Laboratories, Hercules, CA) and transferred to nitrocellulose 
membrane blots (Bio-Rad). After blocking with 5% nonfat milk 
in PBS containing 0.1% Tween 20, membranes were incubated 
with primary antibody, washed, incubated with HRP-conjugated 
goat anti-rabbit IgG or anti-mouse IgG antibodies, and then 
washed again. Signals were detected by chemoluminescence 
(ECL Western Blotting Detection Kit, Amersham Biosciences, 
Barcelona, Spain). Actin signals were used as protein loading and 
transfer references. 
 Real-time RT-PCR 
 Total RNA was extracted with the RNeasy Kit (Qiagen, Venlo, 
Netherlands). Complementary DNAs were synthesized with the 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA). Real-time quantitative PCR assays were 
performed on a LightCycler 480 instrument (Roche Diagnos-
tics, Mannheim, Germany) and analyzed with the LightCycler 
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 Immunohistochemistry 
 The procurement of human tissues complied with Spanish 
legislation regarding informed consent, privacy, and all legal 
requirements after approval by the Hospital Clínic Institu-
tional Ethics Committee. Sections (2 µm thick) were obtained 
for immunohistochemistry either from formalin-fi xed and 
paraffi n-embedded tissue blocks or from tissue microarrays 
(TMA) built with a Manual Tissue Arrayer 1 (Beecher Instru-
ments, Sun Prairie, WI). A total of 33 samples, containing nor-
mal, prostate intraepithelial neoplasia, and carcinomatous 
glands were analyzed. Tissue sections were mounted on xy-
laned glass slides (Thermo Scientifi c, Braunschweig, Germany) 
and used for immunohistochemical staining using the Bond 
Polymer Refi ne Detection System (Leica Microsystems, Wetzlar, 
Germany). Samples were deparaffi nized, antigen retrieval was 
performed at pH 6 for 20 min in citrate buffer, and primary 
antibody was incubated for 1 h at room temperature. Rabbit 
anti-ASAH1 (BD Transduction Laboratories, Franklin Lakes, 
NJ) was used at a dilution of 1/100. Staining was scored as the 
percentage of cells with clear positivity and the predominant 
staining intensity. Images were captured with an Olympus 
BX-51 microscope equipped with an Olympus DP70 camera. 
 Statistical analysis 
 Signifi cance was determined by the two-tailed unpaired  t -test 
using the Graph Pad Prism 4.0 software. 
 RESULTS 
 Increased expression of acid ceramidase in highly 
metastatic clones derived from PC-3 prostate cancer cells 
 The PC-3 prostate cancer cell line was used to gener-
ate two distinct clonal populations. PC-3/S cells were 
isolated in vitro by single-cell cloning from luciferase-
expressing PC-3 cells. A second single-cell progeny, here-
after designated PC-3/Mc, was isolated from luciferase-
expressing PC-3/M cells, a PC-3 subline that had been 
selected in vivo for its high metastatic potential ( 21 ). 
Intramuscular grafting in NOD-SCID mice of 2.5 × 10 5 
PC-3/Mc cells quickly produced large tumors ( Fig. 1A ) 
 with the appearance of abdominal lymph node metasta-
ses by 19 days in 50% of mice ( 21 ). In vitro, PC-3/Mc 
cells grew much faster than PC-3/S cells ( Fig. 1B ). More-
over, PC-3/Mc cells were highly clonogenic, whereas 
PC-3/S cells showed limited anchorage-independent 
growth ( Fig. 1C ). 
 To investigate the sphingolipid profi les of both cell 
lines, cells were seeded (0.25 × 10 6 cells/ml) and grown 
under standard conditions, and their sphingolipid com-
position determined after 48 h of culture. LC/MS analy-
sis showed that total ceramide abundance in PC-3/S cells 
was 1.3-fold that of PC-3/Mc cells ( Fig. 1D ). Interest-
ingly, this difference increased to 2.2 for the C14 and 
C16  N -acyl species (PC-3/S versus PC-3/Mc ratio: 2.2). 
Likewise, the cell content of SM and ceramide mono-
hexosides (CMH, including both glucosylceramides and 
galactosylceramides) was 1.3–1.5 times higher in PC-3/S 
cells than in PC-3/Mc cells ( Fig. 1E, F ), and this differ-
ence was similar for all the differently  N -acylated spe-
cies. No signifi cant differences between free bases and 
 Cell viability assay 
 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, Sigma) was added to cultured cells at a fi nal concentra-
tion of 0.5 mg/ml, incubated at 37°C for 3 h, and the resulting 
precipitates were solubilized with dimethyl sulfoxide. Absorbance 
was measured at 570 nm on a SpectraMax Microplate Reader 
(Molecular Devices, Sunnyvale, CA). 
 Synthesis of novel acid ceramidase inhibitors 
 A solution of 1-hydroxybenzotriazole (18 mg, 0.13 mmol), 
the corresponding carboxylic acid (0.1 mmol), and  N -(3-di-
methylaminopropyl)- N’ -ethylcarbodiimide hydrochloride (20 mg, 
0.13 mmol) in CH 2 Cl 2 (1 ml) was added to a mixture containing 
sphinganine (30 mg, 0.1 mmol), NEt 3 (30 µl, 0.2 mmol) in THF 
or CH 3 CN (1 ml). The resulting solution was stirred for 1 h at 
room temperature and concentrated at reduced pressure. The 
residue was taken up in CH 2 Cl 2 (2 ml), washed with saturated 
aqueous NaHCO 3 solution (3 × 0.5 ml), and then the solvent was 
evaporated to give a crude mixture that was purifi ed by fl ash 
chromatography on silica gel using a gradient of 0–5% CH 2 Cl 2 /
MeOH to afford the pure amide in 70–85% yield. 
 Spectroscopic data for the synthesized compounds: SABRAC : 
 N -[(2 S ,3 R )-1,3-dihydroxyoctadecan-2-yl]2-bromoacetamide. 
 1 H-NMR (400 MHz, CDCl 3 ): 7.40 (1H, NH), 4.20 (2H), 4.05 
(1H), 3.85 (1H), 3.83 (1H), 3.81 (1H), 1.55 (2H), 1.25–1.30 
(26H), 0.88 (t, 3H).  13 C-NMR (101 MHz, CDCl 3 ): 177.2, 74.2, 
62.2, 54.0, 42.8, 34.7, 32.0, 29.8–29.6, 26.0, 22.8, 14.3. RBM1-12: 
 N -[(2 S ,3 R )-1,3-dihydroxyoctadecan-2-yl]2,2-dibromoacetamide. 
 1 H-NMR (400 MHz, CD 3 OD): 6.23 (1H, NH), 3.80 (1H), 3.75 
(2H), 3.65 (1H), 1.44 (2H), 1.25–1.30 (26H), 0.90 (3H). 
 13 C-NMR (101 MHz, CD 3 OD): 166.9, 71.9, 61.7, 57.6, 37.9, 
34.9, 33.1, 30.8–30.5, 26.6, 23.7, 14.5. RBM1-13:  N -[(2 S ,3 R )-1,
3-dihydroxyoctadecan-2-yl]2-methylacrylamide.  1 H-NMR (400 
MHz, CDCl 3 ):   6.75 (1H, NH), 5.72 (1H), 5.38 (1H), 4.05 
(1H), 3.87 (1H), 3.81 (2H), 1.99 (3H), 1.42 (2H), 1.25–1.35 
(26H), 0.88 (3H).  13 C-NMR (101 MHz, CDCl 3 ):   168.6, 139.7, 
120.2, 74.2, 62.3, 53.7, 32.7, 31.8, 29.9–29.3, 25.9, 22.7, 14.1. 
RBM1-15: ( E )-4-[(2 S ,3 R )- N -1,3-dihydroxyoctadecan-2-ylamino]4-
oxo-2-butenoic acid.  1 H-NMR (400 MHz, CDCl 3 ):   7.9 (1H, 
NH), 6.45 (1H), 6.35 (1H), 4.12 (1H), 3.88 (3H), 1.45 (2H), 
1.25 (26H), 0.88 (3H).  13 C-NMR (101 MHz, CDCl 3 ):   166.4, 
166.2, 135.5, 132.5, 73.6, 61.2, 54.7, 34.5, 32.1, 29.8–29.5, 26.1, 
22.8, 14.2. RBM1-16:  N -[(2 S ,3 R )-1,3-dihydroxyoctadecan-2-
yl]3-methyl-2-butenamide.  1 H-NMR (400 MHz, CDCl 3 ):   6.26 
(1H, NH), 5.64 (1H), 4.05 (1H), 3.85 (1H); 3.80 (1H), 2.17 
(3H), 1.86 (3H), 1.54 (2H), 1.25 (26H), 0.88 (3H). 
 13 C-NMR (101 MHz, CDCl 3 ):   167.4, 151.2, 118.5, 74.3, 62.7, 53.9, 
34.7, 32.0, 29.8–29.5, 27.3, 26.1, 22.8, 19.9, 14.2. RBM1-17: (2 E ,4 E )-
N-[(2 S ,3 R )-1,3-dihydroxyoctadecan-2-yl]hexa-2,4-dienamide. 
 1 H-NMR (400 MHz, CDCl 3 ):   7.11 (dd, J = 14.8 Hz, J ′ =10 Hz, 1H), 
6.90 (1H, NH), 6.05 (2H), 5.78 (d, J = 15.2 Hz, 1H), 3.95 (2H), 
3.62 (1H), 1.78 (d, J = 6Hz, 3H), 1.45 (2H), 1.19 (26H), 0.82 (3H). 
 13 C-NMR (101 MHz, CDCl 3 ,CD 3 OD):   167.3, 141.7, 138.2, 129.7, 
121.3, 73.3, 61.9, 54.5, 34.3, 31.9, 29.7–29.3, 26.0, 22.7, 18.5, 14.1. 
RBM1-18: ( E )- N -[(2 S ,3 R )-1,3-dihydroxyoctadecan-2-yl]but-2-en-
amide.  1 H-NMR (400 MHz, CD 3 OD):   6.88 (1H), 6.02 (1H), 5.87 
(d, J = 14.3, 1H), 3.85 (1H), 3.71 (2H), 3.63 (1H), 1.87 (d, J = 6.6, 
3H), 1.52 (2H), 1.25 (26 H), 0.88 (3H).  13 C-NMR (101 MHz, 
CD 3 OD):   168.5, 140.8, 126.2, 72.5, 62.3, 56.9, 35.0, 33.1, 30.9, 
30.7–30.4, 26.9, 23.8, 18.0, 14.6. RBM1-19:  N -[(2 S ,3 R )-1,3-
dihydroxyoctadecan-2-yl]acrylamide.  1 H-NMR (400 MHz, CDCl 3 ): 
  6.33 (d, J = 17.0, 1H), 6.17 (dd, J = 10.2, 16.9, 1H), 5.69 (d, J = 11.1, 
1H), 4.16–3.99 (1H), 3.96–3.71 (3H), 1.68–1.46 (4H), 1.25 (24H), 
0.88 (3H).  13 C-NMR (101 MHz, CDCl 3 ):   165.7, 131.0, 127.3, 74.5, 
62.4, 54.0, 34.7, 32.1, 30.0, 29.7, 29.5, 26.3, 22.8, 14.2. 
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protein and activity levels were not paralleled by signifi cant 
differences at the mRNA level (not shown), suggesting a 
posttranscriptional regulation of ASAH1 expression. 
 Requirement of ASAH1 for optimal growth and 
metastatic potential of PC-3/Mc cells 
 Given the above differential ceramidase activity and 
expression of ASAH1 protein between metastatic and 
nonmetastatic prostate cancer cell clonal populations 
and to determine its importance for the growth and met-
astatic properties of PC-3/Mc cells, we proceeded to stably 
knock down its transcript. Cells were transduced with 
fi ve different lentiviral constructs expressing shRNAs tar-
geting fi ve distinct sequences on the ASAH1 mRNA. 
Three of these shRNAs were effective at specifi cally de-
creasing ASAH1 mRNA levels with variable effi cacies, 
ranging from 90 to 60% ( Fig. 2A ).  This gene knockdown 
was paralleled by a corresponding inhibition of the AC 
activity in these cells ( Fig. 2A ). The silencing effi cacies 
long-chain phosphates were detected between the two 
cell lines (not shown). 
 Enzyme activity determination showed that the highly 
aggressive and metastatic PC-3/Mc cells displayed levels of 
AC activity that were 2.5 to 4 times higher than those of 
PC-3/S cells, determined either in cell lysates at acidic pH 
or in intact cells ( Fig. 1G ) using a fl uorogenic assay ( 22 ). 
Several fi ndings support that the bulk of the ceramidase 
activity detected in these cells is due to AC. First, the fl uo-
rogenic substrates were accepted by neutral ceramidase 
but not by alkaline ceramidases (not shown). Second, 
RBM14-C8, which is a substrate of NC but not of AC, was 
not hydrolyzed by PC-3/Mc cells. Third, the hydrolytic ac-
tivity detected in these cells was lost after treatment with 
SABRAC, which inhibits AC but not NC (see below). Fur-
thermore, PC-3/Mc cells expressed 2- to 4-fold higher lev-
els of the AC ASAH1 than PC-3/S cells, as determined by 
Western blotting ( Fig. 1H ). A comparative transcriptomic 
survey showed that the observed differences in ASAH1 
 Fig.  1. Comparative growth phenotypes and sphingolipid profi les between metastatic PC-3/Mc cells and 
nonmetastatic PC-3/S cells. A: PC-3/Mc cells rapidly grew tumors upon intramuscular inoculation in NOD-
SCID mice, as opposed to the very slow tumor growth of PC-3/S cells. B: In vitro, PC-3/Mc cells grew at a 
much faster rate than PC-3/S cells under standard growth conditions on plastic dishes. C: PC-3/Mc cells 
were very effi cient at growing colonies under anchorage-independent conditions (soft agar), as opposed to 
the poorly clonogenic PC-3/S cells. D–F: PC-3/Mc cells displayed a lower abundance of ceramides (D), 
sphingomyelins (E), and ceramide monohexoses (F) than PC-3/S cells. The lower ceramide content in 
PC-3/Mc cells was statistically signifi cant ( P  	 0.05; unpaired, two-tailed  t -test) for the 14:0, 16:0, 18:0, 20:0, 
and 24:1 species. All SM and CMH species were present at signifi cantly lower levels in PC-3/Mc cells than in 
PC-3/S cells. G: PC-3/Mc cells displayed signifi cantly higher levels of acid ceramidase activity as compared 
with PC-3/S cells, assayed using either intact cells or cell lysates. H: The acid ceramidase ASAH1 was ex-
pressed at signifi cantly higher levels in PC-3/Mc cells than in PC-3/S cells, as determined by Western blot-
ting. Actin signal was used to monitor protein loading and transfer. 
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that PC-3/Mc cells are resistant to the apoptotic and 
growth-inhibitory effects of ceramide accumulation under 
standard growth conditions. Consistently, the growth rate 
of ASAH1-knockdown PC-3/Mc cells in standard growth 
medium (10% FBS) did not differ signifi cantly from that 
of control cells when seeded at initial densities of 1,000 
cells/cm 2 ( Fig. 3A ).  However, when seeded at a density of 
500 cells/cm 2 , ASAH1-knockdown cells showed a signifi -
cantly reduced growth rate compared with control cells 
( Fig. 3B ). This suggests that ASAH1 might be critically re-
quired to sense factors dependent on cell density, includ-
ing paracrine factors or cell-cell interactions. In order to 
know whether ASAH1 knockdown sensitized PC-3/Mc 
cells to limiting concentrations of exogenous growth fac-
tors, their rate of proliferation was determined in medium 
containing 0.5% FBS. Under these conditions, ASAH1-
knockdown PC-3/Mc cells grew at signifi cantly slower rates 
of shRNAs 399 and 402 were confi rmed by Western blot-
ting ( Fig. 2B ). 
 The sphingolipid content of ASAH1-knockdown PC-3/
Mc cells was analyzed by UPLC-TOF. Both ASAH1-specifi c 
shRNAs caused the accumulation of ceramides, SM, and 
CMH compared with cells transduced with a control lenti-
viral vector ( Fig. 2C–E ), indicating an impairment of cer-
amide catabolism, which confi rms the functionality of the 
knockdowns. Unexpectedly, sphingosine was increased 
in both knockdown clones ( Fig. 2F ), which suggests that 
other ceramidases are upregulated upon chronic knock-
down of ASAH1 ( 24 ). 
 We next tested if this accumulation of ceramides pro-
voked an impairment of the growth or viability of ASAH1-
knockdown PC-3/Mc cells. Neither of the two knockdowns 
had any effect on the PC-3/Mc population, nor did they 
cause the accumulation of sub-G1 populations, suggesting 
 Fig.  2. ASAH1 knockdown causes an accumulation of sphingolipids in PC-3/Mc cells. A: Knockdown of 
 ASAH1 mRNA by fi ve distinct shRNAs, determined by qPCR, and of AC activity as determined with RBM14C12 
as a substrate in intact cells. Negative controls were PC-3/Mc cells transduced with lentiviral particles carrying 
a LK0 vector expressing a nontargeting shRNA sequence. Results were normalized to 18S mRNA or amount of 
protein. Values are represented as the mean percentage over control of three replicates ± SD. B: Western blot-
ting confi rmatory of the specifi c and effective knockdown of ASAH1 mRNA by shRNAs 399 and 402. Actin 
signal was used as a control of protein loading and transfer. C–F: Sphingolipid content of PC-3/Mc cells 
knocked down for ASAH1 with shRNAs 399 and 402, showing the accumulation of ceramides (C), sphingomy-
leins (D), ceramide monohexosides (E), and sphingosine (F) compared with control PC-3/Mc-LK0 cells. 
Determinations were carried out by UPLC/TOF. Results are shown as the mean of three values ± SD. 
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PC-3/Mc cells to form tumors in NOD-SCID mice, with 
independence of the initial inoculum size ( Fig. 4A ),  and it 
signifi cantly delayed their ability to colonize lungs upon 
intravenous injection ( Fig. 4B ). 
 Therefore, although PC-3/Mc cells are resistant to the 
effects on survival or the cell cycle caused by ceramide ac-
cumulation following knockdown of ASAH1, they display a 
strong dependence on ASAH1 for the maintenance of key 
properties associated with tumor-initiating cells, namely, 
anchorage-independent growth in vitro and tumorigenesis 
and lung colony formation in immunodefi cient mice. 
 Development of novel, highly specifi c acid 
ceramidase inhibitors 
 The above results support the importance of ASAH1 for 
the self-renewal and metastatic phenotypes of PC-3 pros-
tate cancer cells, and validate it as a potential therapeutic 
than control cells at all initial seeding densities, with more 
pronounced effects at the lowest initial seeding density 
studied ( Fig. 3C, D ). 
 In agreement with the weak effect of ASAH1 knockdown 
on the growth of PC-3/Mc cells in standard culture condi-
tions, only one of the two ASAH1-specifi c shRNAs caused 
a modest decline of the G1 population with an increased 
G2-M population ( Fig. 3E ). The ability of cells to form 
colonies in anchorage-independent conditions is a mea-
sure of their self-renewal potential and is closely related to 
their tumorigenic and metastatic capacities in vivo ( 25 ). As 
described above, the metastatic PC3/Mc cells were strongly 
clonogenic, as opposed to the nonmetastatic PC-3/S cells. 
Knockdown of ASAH1 completely abolished the clono-
genic capacity of PC-3/Mc cells ( Fig. 3F ), indicating that 
ASAH1 is required for their self-renewal. Consistently, 
knockdown of ASAH1 strongly inhibited the ability of 
 Fig.  3. ASAH1 knockdown inhibits the growth of PC-3/Mc cells under low-density and low-serum condi-
tions and abrogates their anchorage-independent colony-forming potential. A–D: Effect of ASAH1 knock-
down by shRNA 399 or 402 on the 2D growth of PC-3/Mc cells. Cells were seeded at the specifi ed initial 
densities on plastic dishes and grown in medium supplemented with either 10% FBS (A, B) or 0.5% FBS 
(C, D). Controls were PC-3/Mc cells transduced with lentiviral particles carrying a LK0 vector expressing a 
nontargeting shRNA sequence. The number of cells was determined with the MTT method at the indicated 
time points after seeding. Data correspond to the mean ± SD of triplicates. Statistical signifi cance: 
* P < 0.05, ** P < 0.005 (two-tailed unpaired  t -test). E: Effect of ASAH1 knockdown on the cell cycle distribution 
of PC-3/Mc cells. Cells stably transduced with the indicated lentiviral particles or a control vector (LK0) were 
analyzed for DNA content by fl ow cytometry and analyzed for cell cycle distribution. Data are represented as 
the mean of triplicates ± SD. F: Effect of ASAH1 knockdown by shRNA 399 or 402 on anchorage-indepen-
dent cell growth of PC-3/Mc cells. Cells were cultured on soft agar, and colonies were stained with crystal vio-
let after three weeks. Data are represented as the mean of triplicates ± SD. 
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experienced an exponential decay versus incubation time 
at the two protein concentrations tested (supplementary 
Fig. I), indicating an irreversible type of inhibition. 
 Neither SABRAC nor RBM1-12 inhibited the activity of 
the cysteine protease papain, whereas chymostatin com-
pletely blocked papain activity at the standard concen-
trations (supplementary Fig. IIA). On the other hand, 
at conditions under which SABRAC inhibited AC, AC 
activity was unaffected by the cysteine protease inhibitor 
E64d (supplementary Fig. IIB). 
 Effects of AC inhibitors on the growth of PC-3/Mc cells 
 We next tested the effects of RBM1-12, RBM1-13, and 
SABRAC on the growth properties of PC-3/Mc cells. First, 
the inhibitory potency of these compounds on AC was 
determined by incubating the cells with increasing doses for 
48 h, and then determining AC activity in cell lysates using 
a fl uorogenic assay. Under these conditions, the inhibi-
tion of AC by RBM1-12 and SABRAC was dose-dependent 
(RBM1-12: 1 µM < IC 50 < 5 µM; SABRAC: IC 50 < 1 µM) 
( Fig. 6A ).  Surprisingly, RBM1-13, which had shown to be a 
good AC inhibitor in FD10X intact cells and cell lysates 
( Fig. 5B ), did not display any AC inhibitory effect in PC-3/
Mc cells. In fact, RBM1-13 tended to enhance the activity 
of AC in these cells ( Fig. 6A ). We do not know the reason 
for this striking difference in the effects of RBM1-13 be-
tween these two cell lines, although differential metabo-
lization or uptake of the compounds in the prostate cancer 
cell lines tested may contribute to the discrepancy. The 
sphingolipid profi les of PC-3/Mc cells after treatment with 
these compounds refl ected their AC inhibitory activities. 
Thus, both RBM1-12 and SABRAC induced an accumulation 
target in hormone-insensitive, metastatic prostate cancer. 
Several AC inhibitors have been synthesized and tested 
with potencies in the low micromolar range. Considering 
that AC is a cysteine hydrolase, a small family of ceramide 
analogs modifi ed at the amide linkage with thiol reactive 
functions was generated and tested. These compounds 
were inspired in reported cysteine protease inhibitors ( 26 ) 
and include two  
 -haloamides and several  
 ,  -unsaturated 
amides as Michael acceptors. Their structures are shown 
in  Fig. 5A . 
 The RBM1 series of compounds was synthesized by  N -
acylation of dihydrosphingosine following standard proce-
dures. All compounds were tested in intact FD10X cells as 
well as in cell lysates at pH 4.5 following the reported fl uo-
rogenic assay ( 22, 27 ). The best inhibitors in intact cells were 
compounds RBM1-12, RBM1-13, RBM1-18, and SABRAC, 
with percentages of inhibition ranging from 50 to 70% 
( Fig. 5B ). Whereas RBM1-12, RBM1-13, and SABRAC main-
tained their inhibitory activities in the in vitro assay, 
RBM1-18 had no inhibitory activity in cell lysates ( Fig. 5B ). 
Therefore, compounds RBM1-12, RBM1-13, and SABRAC 
were selected for further studies. To assess their specifi c-
ity, the three compounds were tested for their effects on 
NC using the standard substrate ( 28 ) and on FD cells tran-
siently transfected with the ASAH2 gene. None of the 
compounds inhibited NC ( Fig. 5C ), attesting to their spec-
ifi city as inhibitors of acid ceramidase. In vitro dose-re-
sponse determinations showed that SABRAC was the best 
inhibitor, with an IC 50 value of 52 nM, followed by RBM1-12 
(IC 50 = 0.53 µM) and RBM1-13, which exhibited the lowest 
potency (IC 50 = 11.2 µM) ( Fig. 5D ). Furthermore, both in 
the presence of SABRAC or RBM1-12, the enzyme activity 
 Fig.  4. ASAH1 knockdown inhibits tumor growth and lung colonization of PC-3/Mc cells in NOD-SCID 
mice. A: Knock down of ASAH1 in PC-3/Mc cells with shRNA 399 strongly inhibits the growth of tumors. 
Controls were PC-3/Mc cells transduced with lentiviral particles carrying a LK0 vector expressing a nontar-
geting shRNA. Cells (2 × 10 5 ) were inoculated intramuscularly in male NOD-SCID mice, and growth was 
monitored by bioluminescence. Upper panel: bioluminescent images of representative mice. Lower panel: 
Growth curves as a function of time (n = 8). B: Knockdown of ASAH1 in PC-3/Mc cells with shRNA 399 sig-
nifi cantly delays lung colonization. Control cells were as in (A). Cells (2 × 10 5 ) were inoculated intravenously 
in male NOD-SCID mice, and lung colonization was monitored by bioluminescence. Upper panel: biolumi-
nescent images of representative mice. Lower panel: Kaplan-Maier plots of lung colonization free-mice as a 
function of time (n = 8). 
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facilitate the removal of the ceramides that accumulate as 
a consequence of ASAH1 silencing. The short-term inhibi-
tion of AC by chemical inhibitors, such as in the above 
experiments, would not allow suffi cient time to trigger 
such hypothetical long-term adaptive responses. 
 These compounds were assessed for their effects on the 
growth of PC-3/Mc cells. At a concentration of 5 µM and 
in medium containing 10% FBS, the growth of PC-3/Mc 
cells was significantly slowed by all the compounds, al-
though RBM1-13 showed the least growth inhibitory activ-
ity at 1 µM ( Fig. 6C ). At 5 µM, the two AC inhibitors active 
on PC-3/Mc cells, RBM1-12 and SABRAC, completely 
abolished the ability of PC-3/Mc cells to form colonies in 
anchorage-independent conditions, while RBM1-13 did 
not show signifi cant effects in these assays ( Fig. 6D ). None 
of the compounds had signifi cant effects at a concentra-
tion of 1 µM, and similar to knockdown of ASAH1, none 
of ceramides ( Fig. 6B ), whereas, as expected for its lack of 
AC inhibitory activity in PC-3/Mc cells, RBM1-13 did not 
signifi cantly alter the abundance of ceramides. 
 The abundance of complex sphingolipids such as SM 
or CMH was not signifi cantly affected by any of the com-
pounds, except for the levels of CMH in cells treated with 
RBM1-12 at 5 µM, which increased 50% over controls 
( Fig. 6B ). This is in contrast with the effect of stably knock-
ing down ASAH1 in PC-3/Mc cells, which caused the ac-
cumulation of these complex sphingolipids ( Fig. 2D, E ). 
In a second discrepancy between transcript knockdown 
and chemical inhibition of AC, levels of sphingosine did 
not change by treatment of PC-3/Mc cells with either 
RBM1-12 or SABRAC (data not shown), whereas they 
increased upon ASAH1 knockdown. We speculate that 
prolonged knockdown of ASAH1 may permit an adap-
tive response of cells by upregulating other ceramidases to 
 Fig.  5. Novel acid ceramidase inhibitors: structures and activities. A: Chemical structure of the compounds. 
B: AC activities as determined in FD10X cells with equimolar concentrations (40 µM) of substrate 
(RBM14C12) and test compound. Control activities correspond to those of FD10X. C: NC activities as mea-
sured in FD cells transfected with pcDNA5/TO_ASAH2 using CerC12NBD as substrate (5 µM) and test 
compounds at 40 µM or vehicle (control). D: Dose-response AC activities of selected compounds on FD10X 
cell lysates assayed with RBM14C12 for 3 h after 5 min incubation with different concentrations of RBM1-12, 
RBM1-13, and SABRAC. Data points correspond to the mean ± SD of two experiments with triplicates. In all 
cases, results were normalized to the amount of protein (in vitro) or number of cells (intact), which was simi-
lar in all cases. Controls were as in (B). Regression analysis of data in (D) (sigmoidal dose-response with 
variable slope) affords IC 50 values of 0.53 µM, 11.2 µM, and 52 nM for RBM1-12, RBM1-13, and SABRAC, 
respectively. 
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 In summary, similar to ASAH1 knockdown, two of the 
newly developed AC inhibitors, RBM1-12 and SABRAC, 
showed strong inhibitory activities on AC activity and on 
the growth and clonogenic capacities of the highly meta-
static PC-3/Mc cells. Interestingly, SABRAC displayed 
strong growth inhibitory effects on PC-3/Mc cells, while 
exhibiting very limited cytotoxicity. A third compound, 
RBM1-13, which had AC inhibitory activity in other cells, 
did not inhibit AC in PC-3/Mc cells, and although it ex-
erted cytotoxic activity on these cells, it had less potent 
inhibitory activity on the growth of these cells on plastic 
and showed no effect on their capacity to grow in anchor-
age-independent conditions. 
 Expression of ASAH1 in nonmetastatic and metastatic 
prostate cancer 
 It has previously been reported that ASAH1 is expressed 
in a number of tumor types, including PC, at levels higher 
than in normal tissues ( 17 ). However, thus far its expres-
sion in PC has not been reported by immunohistochem-
istry, which permits to correlate staining intensities (as 
surrogates of expression levels) with morphological pa-
rameters. We used an ASAH1-specifi c antibody ( Figs. 1H 
and 2B ) to analyze by immunohistochemistry a total of 
33 samples from prostate cancer patients that contained 
tumoral glands, glands with normal morphologies, and 
of the inhibitors caused signifi cant changes in the cell cy-
cle profi le of PC-3/Mc cells (data not shown). 
 Next, the dose-dependent cytotoxic activity of these 
compounds on PC-3/Mc cells was evaluated after 72 h 
incubations. The most toxic compound was RBM1-13 
(CC 50 = 10.0 µM), followed by RBM1-12 (CC 50 = 28.2 µM) 
and SABRAC (CC 50 > 300 µM) (supplementary Fig. III). 
Because RBM1-13 did not show a detectable AC inhibi-
tory activity in PC-3/Mc cells, its cytotoxic activity on 
these cells must be caused by off-target effects. The non-
metastatic PC-3/S clone was more sensitive to the cyto-
toxic effects of SABRAC than were the isogenic, metastatic 
PC-3/Mc cells, (CC 50 = 25.3 µM). In contrast, both clones 
exhibited similar sensitivities to RBM1-12 and RBM1-13 
(CC 50 = 37.4 µM and 14.6 µM, respectively) (supplemen-
tary Fig. III). The cytotoxic activity of these compounds 
was tested on additional pairs of cell lines with different 
tumorigenic or metastatic potentials, including the trans-
formed prostate epithelial cells RWPE-2 (tumorigenic) 
versus RWPE-1 (nontumorigenic), the lung cancer cell 
lines HAL8 (metastatic) versus HAL24 (nonmetastatic), 
and the breast cancer cell lines MDA-MB-231 (metastatic) 
versus MCF-7 (nonmetastatic). The less aggressive cell 
lines were generally more sensitive to the cytotoxic activ-
ity of these acid ceramidase inhibitors than were their 
more aggressive partners (supplementary Fig. III). 
 Fig.  6. Effects of novel ceramidase inhibitors on the AC activity and growth of PC-3/Mc cells. A: AC activity 
of PC3/Mc cells treated with RBM1-12, RBM1-13, or SABRAC. Cells were treated with the compounds at the 
specifi ed concentrations for 48 h, and AC activity was determined in cell lysates with RBM14C12 as the sub-
strate (40 µM). Results, normalized for protein quantity, are shown as the mean of three values ± SD. B: 
Sphingolipid content of PC3/Mc cells treated with 1 or 5 µM RBM1-12, RBM1-13, or SABRAC for 48 h. Re-
sults were normalized for protein quantity and shown as mean of triplicates ± SD. C: Effect of RBM1-12, 
RBM1-13, and SABRAC on the adherent growth of PC-3/Mc cells under standard culture conditions. Cells 
(1,000/cm 2 ) were seeded in 96-well plates, and cell numbers were determined with the MTT method at dif-
ferent time points. Data are represented as the mean of triplicates ± SD. D: Effect of RBM1-12, RBM1-13, and 
SABRAC on the anchorage-independent growth of PC-3/Mc cells. Cells (3 × 10 3 ) were cultured in soft agar 
in the presence of 5 µM of the test compounds or vehicle alone, and then stained with crystal violet after 
three weeks. Images were captured and processed with ImageJ, and colonies   0.2 mm diameter were scored. 
Data are represented as the mean of triplicates ± SD. 
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with histological grade (Gleason score), stage, or the pres-
ence of lymph node metastasis. However, the observation 
that strong expression of ASAH1 was associated with the 
preneoplastic PIN lesions more than with normal glands 
and in turn with prostate adenocarcinoma more than with 
PIN lesions suggests that ASAH1 expression levels tend to 
increase during PC progression. 
 DISCUSSION 
 Advanced, hormone-independent, castration-resistant 
prostate cancer represents a devastating form of the dis-
ease that frequently develops from initially less aggressive 
tumors and shows resistance to conventional chemothera-
peutic agents ( 18–20 ). In this evolutive process, the pro-
gressive dominance in the tumor of cancer stem cells, 
endowed with high survival and low drug sensitivity ( 25, 29 ), 
is emerging as crucial. 
 Here, we studied the clonal population PC-3/Mc, 
derived from prostate cancer cells and highly enriched 
in tumor-initiating cells ( 21 ), and found that its growth 
and clonogenic potential are extremely sensitive to the 
knockdown of ASAH1 or chemical inhibition of AC ac-
tivity. In addition, knockdown of ASAH1 in these cells 
strongly inhibited their capacity to grow tumors upon lo-
cal implantation or to colonize lungs after intravenous 
injection. Although the growth of PC-3/Mc cells under ad-
herent conditions was also affected by ASAH1 knockdown, 
it was made most evident only upon deprivation of growth 
factors, suggesting that ASAH1 is required for optimal 
glands with characteristics of the preneoplastic lesion 
prostate intraepithelial neoplasia (PIN). All epithelial 
structures stained for ASAH1, albeit at varying intensities 
( Fig. 7A –C ).  In a range of staining intensities from 1 to 3, 
most normal or neoplastic structures were given an inten-
sity score of 2 (72.7% of normal glands, 75% of PIN, and 
63.6% of tumoral glands;  Fig. 7D and supplementary Table I). 
However, only 1 out of 22 evaluable cases with normal 
glands was scored as intensity 3 (4.5%), while 4 of 24 
(16.7%) of PIN glands and 10 of 33 (30.3%) of tumoral 
glands were scored as intensity 3 ( Fig. 7D and supplemen-
tary Table II). In those cases in which normal and tumoral 
glands could be evaluated simultaneously in the same sam-
ple (22 cases), the ASAH1 staining intensities of normal 
versus tumoral glands were scored as equal in 10 cases 
(45.5%), the staining intensity was scored as stronger in 
tumoral glands versus normal glands in 8 cases (36.4%), 
and in 4 cases (18.2%), the maximum intensity in tumoral 
glands was scored as lower than the maximum intensity in 
normal glands ( Fig. 7E and supplementary Table II). In 
several cases, the staining intensity for ASAH1 in tumoral 
areas was clearly stronger than the staining in adjacent 
normal glands ( Fig. 7C, E ). 
 Thus, strong ASAH1 immunostaining in human pros-
tate tissues tended to be associated with prostate adeno-
carcinoma ( Fig. 7D ), an observation that complements 
previous reports in which immunohistochemical analysis 
was not performed, and thus the specifi c cell type, either 
epithelial or stromal, expressing ASAH1 was not deter-
mined ( 17 ). On the other hand, with the cases studied 
here, stronger ASAH1 staining did not show correlations 
 Fig.  7. Immunohistochemical analysis of ASAH1 expression in prostate cancer. A–C: Staining for ASAH1 with 
a specifi c antibody of 33 cases of prostate cancer showed expression in normal glands (A), glands with prostate 
intraepithelial neoplasia or PIN (B), and adenocarcinomatous glands (C), with frequent (36.4% of cases) stron-
ger staining in tumoral (T) than in morphologically normal (N) glands. D: Stronger staining (intensity 3) was 
observed more frequently in adenocarinomatous glands (Tumor) than in PIN and morphologically normal 
glands. E: In samples in which tumoral and morphologically normal glands were analyzed simultaneously, the 
staining intensities were scored as equal in tumoral versus normal glands in 45.5%, as stronger in tumoral versus 
normal glands in 36.4%, and as weaker in tumoral versus normal glands in 18.2% of cases. 
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Because of this different enzyme compartmentalization, 
the increase in SM and CMH is unlikely to arise from 
augmented synthesis from the lysosomal ceramide. A 
plausible explanation involves downregulation of lyso-
somal acid sphingomyelinase and glucocerebrosidase as 
a result of intralysosomal ceramide buildup. Interestingly, 
the sphingolipid profi le of the PC-3/Mc cells knocked 
down for AC is similar to that seen in PC-3/S cells. This 
fi nding supports that the accumulation of sphingolipids 
inside the lysosome as a result of different AC activities in 
both clones is related to the different aggressiveness of the 
two phenotypes. 
 The growing recognition of AC as a potential therapeu-
tic target in cancer has encouraged the development of 
AC inhibitors ( 12 ). AC belongs to the  N -terminal nucleo-
phile (Ntn) hydrolase family ( 48 ). This family of enzymes 
shares the common feature of having an  N -terminal nu-
cleophile, which is generated by autoproteolytic process-
ing ( 49 ). The Cys143 nucleophilic thiol in AC is exposed 
at the  N -terminus of the   -subunit after cleavage of the 
precursor protein. Therefore, AC belongs to the same sub-
category of Ntn hydrolases as the cysteine proteases. Based 
on this relationship, AC has been recently found to be in-
hibited by the cysteine protease inhibitors, cystatins ( 50 ). 
During the course of this study, we identifi ed novel po-
tent and specifi c inhibitors of AC within a series of small 
molecules inspired in reported irreversible cyteine pro-
tease inhibitors ( 51–53 ). These compounds feature either 
an  
 -halocarbonyl unit or an  
 ,  -double-bond Michael 
acceptor moiety. The fi rst screening in cells overexpress-
ing AC showed that, among the compounds prepared, the 
 
 -bromoamides RBM1-12 and SABRAC were the most po-
tent inhibitors. Within the  
 ,  -unsaturated amides, only 
the methacrylamide (RBM1-13) elicited AC inhibitory ac-
tivities both in intact cells and cell lysates. None of the 
compounds was active on NC, consistent with their con-
ception as thiol-targeting molecules. The low potencies 
of the other  
 ,  -unsaturated amides relative to RBM1-13 
suggest that substitution at the   -position hinders the at-
tack of the enzyme nucleophilic thiolate. Surprisingly, 
acrylamide RBM1-19 had no activity as AC inhibitor. Al-
though the reasons for this fi nding have not been investi-
gated, it is possible that the high reactivity of unsubstituted 
acrylamides results in alternative reactions of RBM1-19 
before reaching the AC target. The activity of the bromo-
amides is especially relevant. SABRAC and RBM1-12 are 
among the most potent AC inhibitors so far reported 
( 54 ), with IC 50 values of 52 nM and 530 nM, respectively, 
as assayed with lysates of cells overexpressing AC. Time 
dependence of inhibition supported that both SABRAC 
and RBM1-12 are irreversible inhibitors, which agrees 
with the expected mechanism considering their structure 
and the involvement of a nucleophilic cysteine residue in 
the catalytic site. Furthermore, they are inactive over both 
NC and papain, a cysteine protease, thus supporting their 
selectivity for AC. 
 Both SABRAC and RBM1-12 were also potent inhibitors 
of AC in intact PC-3/Mc cells. Surprisingly, RBM1-13, 
which inhibited AC in FD10X cells, failed to inhibit AC in 
growth of PC-3/Mc cells under limited growth factor supply 
but is dispensable for adherent growth when growth factors 
are present at high concentrations. These results, together 
with the strong phenotype that we observed in anchor-
age-independent growth assays, which correlates with self-
renewal, tumorigenic, and metastatic potentials ( 21, 25 ) 
for both ASAH1 knockdown and AC inhibition, suggest 
that AC is required for self-renewal and growth factor sig-
naling in drug-resistant and metastatic PC-3/Mc prostate 
cancer cells. 
 That ASAH1 knockdown and inhibition of AC produces 
a specifi c effect on a particular growth property of PC-3/
Mc cells, namely, anchorage-independent spheroid forma-
tion, is further supported by the absence of signifi cant 
cell death or the accumulation of sub-G1 cell popula-
tions, in spite of the expected accumulation of ceramides. 
Additionally, neither ASAH1 knockdown nor AC inhibi-
tion caused a signifi cant sensitization of PC-3/Mc cells to 
drugs used in advanced prostate cancer therapy, includ-
ing docetaxel, doxorubicin, and etoposide (supplemen-
tary Fig. IV), which confi rms the chemoresistance of this 
highly aggressive subpopulation of prostate cancer cells 
enriched in tumor-initiating cells unaffected by the accu-
mulation of ceramides. The failure of AC inhibition or 
ASAH1 knockdown to chemosensitize PC-3/Mc cells dif-
fers from the sensitization found in various other tumor 
cells ( 30–39 ). In PC-3/Mc cells, AC inhibition or ASAH1 
knockdown may upregulate specifi c pathways to metabo-
lize the resulting ceramide excess. Such pathways include 
phosphorylation, glycosylation, and conversion into SM. 
The possibility of phosphorylation as a tumor death escape 
route ( 40 ) does not seem plausible, as no ceramide-1-
phosphate was ever detected in PC-3/Mc cells, regardless 
of any genetic manipulation or chemical treatment. In 
contrast, most SM and CMH species are signifi cantly 
higher in ASAH1-knockdown cells than in mock cells. 
Although SM synthases have been seldom addressed as 
targets to overcome resistance ( 41, 42 ), the usefulness of 
inhibition of glucosyltransferases as a means to exploit 
ceramide as an antitumor agent has been extensively doc-
umented ( 43, 44 ). Furthermore, chemoresistance is not 
only the result of ceramide clearance by glycosylation but 
also the increased glycosylation products themselves have 
been reported to upregulate the expression of multi-
drug resistant protein 1 (MDR1) through c-Src kinase and 
  -catenin signaling ( 45 ). Whether UDP-glucose ceramide 
glucosyltransferase (UGCG) or MDR1 is upregulated upon 
ASAH1 silencing in PC-3/Mc cells has not been investi-
gated. However, the UGCG transcript levels are higher in 
PC-3/S than in PC-3/Mc cells (unpublished observations), 
as opposed to their AC activity. 
 Nevertheless, the signifi cant increase in SM and CMH 
in PC-3/Mc cells knocked down for AC deserves comment. 
Because AC is a lysosomal enzyme and ceramides cannot 
exit from the lysosome ( 46 ), a lack of AC activity leads 
to an intralysosomal accumulation of ceramide. However, 
sphingomyelin synthase 2 is localized in the plasma mem-
brane, whereas sphingomyelin synthase 1 and glucosylcer-
amide synthase reside in the Golgi apparatus ( 14, 47 ). 
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the PC-3/Mc cell line. This difference is likely due to the 
different incubation times (FD10X, 4 h; PC3Mc, 48 h) 
pointing to the metabolization of RBM1-13 after long-term 
incubations. In contrast, the bromoamides maintained 
their inhibitory activity at long incubation times. In agree-
ment with their AC inhibitory activity, both SABRAC and 
RBM1-12 induced a buildup of ceramides, which was sig-
nifi cant compared with controls for all the different  N -acyl 
species. However, levels of sphingosine remained unaf-
fected. The latter results, although unexpected for AC 
inhibitors, are not unprecedented. Bielawska et al. ( 55 ) re-
ported that the sphingolipid profi les of MCF-7 cells treated 
with different ceramidase inhibitors derived from B13 and 
D-e-MAPP followed different patterns depending on the 
chemical function substituted for the original amide. In the 
case of an  N -alkyl analog of D-e-MAPP, namely, compound 
LCL284, ceramides accumulated, but long chain bases 
did not change signifi cantly. A plausible explanation is the 
triggering of compensatory mechanisms to keep bioactive 
sphingolipids at nonlethal levels. One such mechanism 
could involve an increased activity of other ceramidases. A 
similar scenario might lead to the slight increase of sphin-
gosine found in PC-3/Mc cells knocked down for AC. In 
support of this hypothesis, Hu et al. ( 24 ) demonstrated that 
knockdown of the alkaline ceramidase 3 upregulated the 
expression of the alkaline ceramidase 2 with increases of 
both sphingosine and its phosphate. 
 Our fi ndings support the notion that ceramidase me-
tabolism ( 56 ) and, more specifi cally, acid ceramidase ac-
tivity, are critical regulators of the self-renewal, tumorigenic, 
and metastatic potentials of cancer stem cells, represented 
by the PC-3/Mc population ( 21 ), beyond their known reg-
ulation of signals that tilt the balance between cell survival 
and death. Furthermore, we argue that our cellular model, 
specifi cally selected for subpopulations with strong self-
renewal and aggressive phenotypes, allows to better ad-
dress therapeutic strategies against advanced cancer ( 45 ). 
The precise mechanism linking the elevated AC activity 
and the increased aggressiveness of PC-3/Mc cells com-
pared with the PC-3/S clone is under investigation.  
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